<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599812447048</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599812447048</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Head and Neck Surgery</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Distant Metastases and Survival Prediction in Head and Neck Squamous Cell Carcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Lee</surname><given-names>Dong Hwan</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812447048">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Min Joo</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812447048">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Roh</surname><given-names>Jong-Lyel</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812447048">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Sung-Bae</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0194599812447048">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Choi</surname><given-names>Seung-Ho</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812447048">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nam</surname><given-names>Soon Yuhl</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812447048">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Sang Yoon</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812447048">1</xref>
<xref ref-type="aff" rid="aff3-0194599812447048">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599812447048"><label>1</label>Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea</aff>
<aff id="aff2-0194599812447048"><label>2</label>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea</aff>
<aff id="aff3-0194599812447048"><label>3</label>Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea</aff>
<author-notes>
<corresp id="corresp1-0194599812447048">Jong-Lyel Roh, MD, PhD, Department of Otolaryngology, Asan Medical Center, University of Ulsan, College of Medicine, Asanbyeongwon-gil 86, Songpa-gu, Seoul 138-736, Republic of Korea Email: <email>rohjl@amc.seoul.kr</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>147</volume>
<issue>5</issue>
<fpage>870</fpage>
<lpage>875</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>28</day>
<month>3</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>4</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0194599812447048">
<title>Objective</title>
<p>This study was designed to identify the risk factors associated with distant metastases (DM) and survival outcomes in patients with head and neck squamous cell carcinoma (HNSCC).</p>
</sec>
<sec id="section2-0194599812447048">
<title>Study Design</title>
<p>Database analysis plus chart review.</p>
</sec>
<sec id="section3-0194599812447048">
<title>Setting</title>
<p>Tertiary care academic medical center.</p>
</sec>
<sec id="section4-0194599812447048">
<title>Subjects and Methods</title>
<p>Four hundred four eligible patients were involved who were treated with a minimum 2-year follow-up from January 2005 through August 2009. Confirmation of DM was performed by histopathology or follow-up imaging. Univariate and multivariate analyses were used for factors predictive of DM. The survival of patients was calculated by the Kaplan-Meier method.</p>
</sec>
<sec id="section5-0194599812447048">
<title>Results</title>
<p>Thirty-six of the 404 eligible patients (8.9%) developed DM, most frequently in the lungs (80.6%). Univariate analyses revealed that T and N classifications, lymphovascular invasion and perineural invasion of the primary tumor, and locoregional recurrences were each significantly associated with the development of DM (<italic>P</italic> &lt; .05). Multivariate analyses showed that T and N classifications and locoregional recurrences were independent predictors of DM (<italic>P</italic> &lt; .05). The overall 1- and 2-year survival rates of the 36 patients with DMs were 40.6% and 13.5%, respectively. Metastases to more than 1 organ negatively affected patient survival (<italic>P &lt;</italic> .001).</p>
</sec>
<sec id="section6-0194599812447048">
<title>Conclusion</title>
<p>Patients with advanced tumors, nodal involvement, or locoregional recurrences may require more frequent surveillance for the development of DMs.</p>
</sec>
</abstract>
<kwd-group>
<kwd>distant metastasis</kwd>
<kwd>head and neck</kwd>
<kwd>squamous cell carcinoma</kwd>
<kwd>distant metastasis</kwd>
<kwd>risk factors</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, being newly diagnosed in more than half a million patients per year.<sup><xref ref-type="bibr" rid="bibr1-0194599812447048">1</xref>,<xref ref-type="bibr" rid="bibr2-0194599812447048">2</xref></sup> HNSCC is mainly a locoregional disease, confined to the head and neck region and curable with a combination of surgery, radiotherapy, and chemotherapy. Distant metastases (DM) are rarely observed in patients with HNSCC and are associated with extremely poor prognosis. These patients are seldom cured and are offered only palliative treatments. Prevention and/or early detection of DMs may improve the survival of these patients.<sup><xref ref-type="bibr" rid="bibr3-0194599812447048">3</xref></sup> Identifying factors predictive of DM may lead to early detection and the planning of proper treatments.</p>
<p>The overall incidence of clinically detected DM in HNSCC patients is 2.8% to 23.8%, with the lung, bone, and liver being the most common sites.<sup><xref ref-type="bibr" rid="bibr4-0194599812447048">4</xref><xref ref-type="bibr" rid="bibr5-0194599812447048"/><xref ref-type="bibr" rid="bibr6-0194599812447048"/>-<xref ref-type="bibr" rid="bibr7-0194599812447048">7</xref></sup> Risk factors for DM in these patients include the primary tumor site, initially advanced stage, locoregional control, and nodal status.<sup><xref ref-type="bibr" rid="bibr4-0194599812447048">4</xref><xref ref-type="bibr" rid="bibr5-0194599812447048"/><xref ref-type="bibr" rid="bibr6-0194599812447048"/><xref ref-type="bibr" rid="bibr7-0194599812447048"/><xref ref-type="bibr" rid="bibr8-0194599812447048"/><xref ref-type="bibr" rid="bibr9-0194599812447048"/><xref ref-type="bibr" rid="bibr10-0194599812447048"/>-<xref ref-type="bibr" rid="bibr11-0194599812447048">11</xref></sup> Although several studies have assessed the risk factors for DM in HNSCC patients, these studies have identified different sets of risk factors. Better determination of these factors may enhance early identification and proper patient management. We therefore sought to identify the risk factors in HNSCC patients associated with the development of DM and to determine the survival outcomes of these patients.</p>
<sec id="section7-0194599812447048" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>We evaluated patients with HNSCC who were treated at Asan Medical Center from January 2005 through August 2009. All patients underwent metastatic workup with whole-body <sup>18</sup>F-florodeoxyglucose (FDG)–positron emission tomography (PET)/computed tomography (CT) and/or bone scan and chest CT at initial staging and during follow-up after treatment. Primary tumor sites included the oral cavity, oropharynx, larynx, and hypopharynx. Patients with cancers arising in the nasal cavity, paranasal sinus, and an unknown site, as well as those with multiple primary sites and those histologically shown to have nonmetastatic carcinoma in situ, were excluded. We also excluded patients lost to follow-up within 2 years of initial presentation. DMs were confirmed by histopathology or follow-up imaging, including whole-body FDG-PET/CT, bone scan, chest CT, or other methods. This study was reviewed and approved by the Institutional Review Board of Asan Medical Center.</p>
<p>Data obtained from medical records included patient age and gender, sites and TNM stage of the primary tumor, time from diagnosis of the primary tumor to the diagnosis of DM, DM sites, initial treatments, histology of primary tumors and metastatic lymph nodes, and treatment and survival of patients with DM.</p>
<p>Statistical analysis was performed using SPSS software (version 18.0, SPSS Inc, Chicago, Illinois). Univariate analysis of each variable with DM was performed using the 2-sided Fisher exact or the χ<sup>2</sup> test for categorical variables and the Mann-Whitney <italic>U</italic> test for continuous variables. For multivariate analysis, variables with <italic>P</italic> values &lt;.05 on univariate analysis were entered into a binary logistic regression model to determine the variables independently associated with DM. A <italic>P</italic> value &lt;.05 was considered statistically significant. To identify factors associated with 2-year survival in patients with DM, each variable was analyzed using the log-rank test. The overall survival of patients with DM was calculated by the Kaplan-Meier method. A Cox-proportional hazard model was used to identify independent predictors of overall survival.</p>
</sec>
<sec id="section8-0194599812447048" sec-type="results">
<title>Results</title>
<sec id="section9-0194599812447048">
<title>Incidence and Sites of DM</title>
<p>During the study period, 14 patients who were lost to follow-up within 2 years of initial presentation were excluded. Finally, 404 eligible patients were diagnosed with HNSCC, consisting of 334 men and 70 women, of a median 59 years of age (range, 20–87 years; <xref ref-type="table" rid="table1-0194599812447048"><bold>Table 1</bold></xref>). All patients were of a single ethnic group, residing in South Korea. The primary tumor sites were the larynx (47.5%), oral cavity (27.0%), oropharynx (19.1%), and hypopharynx (6.4%). Of these 404 patients, 133 (32.9%) had T3-4 stage tumors, 157 (38.9%) had N+ tumors, and 211 (52.2%) were in advanced TNM stage III-IV. DM developed in 36 (8.7%) patients, 5 (1.2%) at initial staging and 31 (7.5%) after a median follow-up of 12 months (range, 2-38 months). The most common site of DM was the lung (80.6%), followed by the bone (38.9%) and liver (11.1%; <xref ref-type="table" rid="table2-0194599812447048"><bold>Table 2</bold></xref>). Twelve of the 36 (33.3%) patients had DMs in more than 1 organ.</p>
<table-wrap id="table1-0194599812447048" position="float">
<label>Table 1.</label>
<caption><p>Characteristics of Patients with/without Distant Metastases</p></caption>
<graphic alternate-form-of="table1-0194599812447048" xlink:href="10.1177_0194599812447048-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">DM (–)<hr/></th>
<th align="center" colspan="2">DM (+)<hr/></th>
<th/>
</tr>
<tr>
<th align="left">Variable</th>
<th align="center">No.</th>
<th align="center">%</th>
<th align="center">No.</th>
<th align="center">%</th>
<th align="center"><italic>P</italic><sup><xref ref-type="table-fn" rid="table-fn2-0194599812447048">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td/>
<td/>
<td/>
<td/>
<td>.083</td>
</tr>
<tr>
<td> Male</td>
<td>308</td>
<td>92.2</td>
<td>26</td>
<td>7.8</td>
<td/>
</tr>
<tr>
<td> Female</td>
<td>60</td>
<td>85.7</td>
<td>10</td>
<td>14.3</td>
<td/>
</tr>
<tr>
<td>Median age, y (range)</td>
<td colspan="2">59 (20-87)</td>
<td colspan="2">57 (31-78)</td>
<td>.613</td>
</tr>
<tr>
<td>T classification</td>
<td/>
<td/>
<td/>
<td/>
<td>&lt;.001</td>
</tr>
<tr>
<td> T1</td>
<td>179</td>
<td>97.3</td>
<td>5</td>
<td>2.7</td>
<td/>
</tr>
<tr>
<td> T2</td>
<td>79</td>
<td>90.8</td>
<td>8</td>
<td>9.2</td>
<td/>
</tr>
<tr>
<td> T3</td>
<td>55</td>
<td>85.9</td>
<td>9</td>
<td>14.1</td>
<td/>
</tr>
<tr>
<td> T4</td>
<td>55</td>
<td>79.7</td>
<td>14</td>
<td>20.3</td>
<td/>
</tr>
<tr>
<td>N classification</td>
<td/>
<td/>
<td/>
<td/>
<td>&lt;.001</td>
</tr>
<tr>
<td> N0</td>
<td>241</td>
<td>97.6</td>
<td>6</td>
<td>2.4</td>
<td/>
</tr>
<tr>
<td> N1</td>
<td>37</td>
<td>80.4</td>
<td>9</td>
<td>19.6</td>
<td/>
</tr>
<tr>
<td> N2</td>
<td>86</td>
<td>81.1</td>
<td>20</td>
<td>18.9</td>
<td/>
</tr>
<tr>
<td> N3</td>
<td>4</td>
<td>80.0</td>
<td>1</td>
<td>20.0</td>
<td/>
</tr>
<tr>
<td>Overall TNM stage</td>
<td/>
<td/>
<td/>
<td/>
<td>&lt;.001</td>
</tr>
<tr>
<td> I</td>
<td>151</td>
<td>97.4</td>
<td>4</td>
<td>2.6</td>
<td/>
</tr>
<tr>
<td> II</td>
<td>37</td>
<td>97.4</td>
<td>1</td>
<td>2.6</td>
<td/>
</tr>
<tr>
<td> III</td>
<td>56</td>
<td>88.9</td>
<td>7</td>
<td>11.1</td>
<td/>
</tr>
<tr>
<td> IV</td>
<td>124</td>
<td>83.8</td>
<td>24</td>
<td>16.2</td>
<td/>
</tr>
<tr>
<td>Diagnosis of DM</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> At initial staging</td>
<td>0</td>
<td/>
<td>5</td>
<td/>
<td/>
</tr>
<tr>
<td> Follow-up (median months)</td>
<td>0</td>
<td/>
<td>31 (12)</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599812447048">
<p>Abbreviations: DM, distant metastasis; TNM, tumor-node-metastasis (AJCC 6th edition).</p>
</fn>
<fn id="table-fn2-0194599812447048">
<label>a</label>
<p>By the 2-sided Fisher exact test or the χ<sup>2</sup> test except for age (Mann-Whitney <italic>U</italic> test).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0194599812447048" position="float">
<label>Table 2.</label>
<caption><p>Distribution of Sites of Distant Metastases (n = 36)</p></caption>
<graphic alternate-form-of="table2-0194599812447048" xlink:href="10.1177_0194599812447048-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">No. of Patients (%)<hr/></th>
</tr>
<tr>
<th align="left">Site</th>
<th align="center">1 Site (n = 24)</th>
<th align="center">More Than 1 Site (n = 12)</th>
<th align="center">Total (N = 36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung</td>
<td>19 (79.2)</td>
<td>10 (83.3)</td>
<td>29 (80.6)</td>
</tr>
<tr>
<td>Bone</td>
<td>4 (16.7)</td>
<td>10 (83.3)</td>
<td>14 (38.9)</td>
</tr>
<tr>
<td>Liver</td>
<td>1 (4.2)</td>
<td>3 (25.0)</td>
<td>4 (11.1)</td>
</tr>
<tr>
<td>Brain</td>
<td>0</td>
<td>2 (16.7)</td>
<td>2 (5.6)</td>
</tr>
<tr>
<td>Kidney</td>
<td>0</td>
<td>2 (16.7)</td>
<td>2 (5.6)</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>0</td>
<td>1 (8.3)</td>
<td>1 (2.8)</td>
</tr>
<tr>
<td>Spleen</td>
<td>0</td>
<td>1 (8.3)</td>
<td>1 (2.8)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section10-0194599812447048">
<title>Univariate and Multivariate Analyses of Variables Predicting DM</title>
<p>The univariate analyses of variables predictive of DM are shown in <xref ref-type="table" rid="table1-0194599812447048"><bold>Tables 1</bold></xref> and <xref ref-type="table" rid="table3-0194599812447048"><bold>3</bold></xref>. Gender and age were not risk factors (<italic>P</italic> &gt; .05), whereas DM was associated with advanced T, N, and overall TNM stage (<italic>P</italic> &lt; .005 each). DM were significantly more frequent in patients with than without locoregional recurrences (20.5% vs 6.1%, <italic>P</italic> &lt; .001), as were lymphovascular (17.5% vs 7.5%, <italic>P</italic> = .036) and perineural (21.4% vs 7.5%, <italic>P</italic> = .013) invasion of primary tumors. However, primary tumor sites, tumor differentiation, and extracapsular spread of nodes were not predictive of DM (<italic>P</italic> &gt; .05 each). DM was also not associated with the number of pathologic nodes, levels with pathologic nodes (single vs multiple), positive nodes at levels III-IV, types of initial treatment (surgical vs nonsurgical), or chemotherapy. On multivariate analyses, advanced T stage, the presence of metastatic cervical lymph nodes, and locoregional recurrences were independently associated with the development of DM (<italic>P</italic> &lt; .05 each; <xref ref-type="table" rid="table4-0194599812447048"><bold>Table 4</bold></xref>).</p>
<table-wrap id="table3-0194599812447048" position="float">
<label>Table 3.</label>
<caption><p>Univariate Analyses of Clinicopathologic Factors Predictive of Distant Metastases</p></caption>
<graphic alternate-form-of="table3-0194599812447048" xlink:href="10.1177_0194599812447048-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">DM (–)<hr/></th>
<th align="center" colspan="2">DM (+)<hr/></th>
<th/>
</tr>
<tr>
<th align="left">Variable</th>
<th align="left">No.</th>
<th align="center">%</th>
<th align="center">No.</th>
<th align="center">%</th>
<th align="center"><italic>P</italic><sup><xref ref-type="table-fn" rid="table-fn4-0194599812447048">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td/>
<td/>
<td/>
<td/>
<td>.351</td>
</tr>
<tr>
<td> ≤60</td>
<td>195</td>
<td>89.9</td>
<td>22</td>
<td>10.1</td>
<td/>
</tr>
<tr>
<td> &gt;60</td>
<td>173</td>
<td>92.5</td>
<td>14</td>
<td>7.5</td>
<td/>
</tr>
<tr>
<td>T classification</td>
<td/>
<td/>
<td/>
<td/>
<td>&lt;.001</td>
</tr>
<tr>
<td> T1-2</td>
<td>258</td>
<td>95.2</td>
<td>13</td>
<td>4.8</td>
<td/>
</tr>
<tr>
<td> T3-4</td>
<td>110</td>
<td>82.7</td>
<td>23</td>
<td>17.3</td>
<td/>
</tr>
<tr>
<td>N classification</td>
<td/>
<td/>
<td/>
<td/>
<td>&lt;.001</td>
</tr>
<tr>
<td> N0</td>
<td>241</td>
<td>97.6</td>
<td>6</td>
<td>2.4</td>
<td/>
</tr>
<tr>
<td> N+</td>
<td>127</td>
<td>80.9</td>
<td>30</td>
<td>19.1</td>
<td/>
</tr>
<tr>
<td>Primary tumor site</td>
<td/>
<td/>
<td/>
<td/>
<td>.099</td>
</tr>
<tr>
<td> Larynx</td>
<td>179</td>
<td>93.2</td>
<td>13</td>
<td>6.8</td>
<td/>
</tr>
<tr>
<td> Oral cavity</td>
<td>96</td>
<td>88.1</td>
<td>13</td>
<td>11.9</td>
<td/>
</tr>
<tr>
<td> Oropharynx</td>
<td>72</td>
<td>93.5</td>
<td>5</td>
<td>6.5</td>
<td/>
</tr>
<tr>
<td> Hypopharynx</td>
<td>21</td>
<td>80.8</td>
<td>5</td>
<td>19.2</td>
<td/>
</tr>
<tr>
<td>Differentiation of tumors</td>
<td/>
<td/>
<td/>
<td/>
<td>.439</td>
</tr>
<tr>
<td> Well (G1)</td>
<td>164</td>
<td>92.1</td>
<td>14</td>
<td>7.9</td>
<td/>
</tr>
<tr>
<td> Moderate (G2)</td>
<td>175</td>
<td>91.1</td>
<td>17</td>
<td>8.9</td>
<td/>
</tr>
<tr>
<td> Poorly (G3)</td>
<td>29</td>
<td>85.3</td>
<td>5</td>
<td>14.7</td>
<td/>
</tr>
<tr>
<td>LVI of primary tumors<sup><xref ref-type="table-fn" rid="table-fn5-0194599812447048">b</xref></sup></td>
<td/>
<td/>
<td/>
<td/>
<td>.036</td>
</tr>
<tr>
<td> Yes</td>
<td>33</td>
<td>82.5</td>
<td>7</td>
<td>17.5</td>
<td/>
</tr>
<tr>
<td> No</td>
<td>248</td>
<td>92.5</td>
<td>20</td>
<td>7.5</td>
<td/>
</tr>
<tr>
<td>PNI of primary tumors<sup><xref ref-type="table-fn" rid="table-fn5-0194599812447048">b</xref></sup></td>
<td/>
<td/>
<td/>
<td/>
<td>.013</td>
</tr>
<tr>
<td> Yes</td>
<td>22</td>
<td>78.6</td>
<td>6</td>
<td>21.4</td>
<td/>
</tr>
<tr>
<td> No</td>
<td>259</td>
<td>92.5</td>
<td>21</td>
<td>7.5</td>
<td/>
</tr>
<tr>
<td>Extracapsular spread of nodes<sup><xref ref-type="table-fn" rid="table-fn5-0194599812447048">b</xref></sup></td>
<td/>
<td/>
<td/>
<td/>
<td>.990</td>
</tr>
<tr>
<td> Yes</td>
<td>27</td>
<td>81.8</td>
<td>6</td>
<td>18.2</td>
<td/>
</tr>
<tr>
<td> No</td>
<td>76</td>
<td>81.7</td>
<td>17</td>
<td>18.3</td>
<td/>
</tr>
<tr>
<td>No. of pathologic node<sup><xref ref-type="table-fn" rid="table-fn5-0194599812447048">b</xref></sup></td>
<td/>
<td/>
<td/>
<td/>
<td>.570</td>
</tr>
<tr>
<td> 1-2</td>
<td>56</td>
<td>83.6</td>
<td>11</td>
<td>16.4</td>
<td/>
</tr>
<tr>
<td> &gt;2</td>
<td>47</td>
<td>79.7</td>
<td>12</td>
<td>20.3</td>
<td/>
</tr>
<tr>
<td>No. of levels with pathologic nodes<sup><xref ref-type="table-fn" rid="table-fn5-0194599812447048">b</xref></sup></td>
<td/>
<td/>
<td/>
<td/>
<td>.062</td>
</tr>
<tr>
<td> 1</td>
<td>58</td>
<td>87.9</td>
<td>8</td>
<td>12.1</td>
<td/>
</tr>
<tr>
<td> &gt;1</td>
<td>45</td>
<td>75.0</td>
<td>15</td>
<td>25.0</td>
<td/>
</tr>
<tr>
<td>Positive node in levels III–IV<sup><xref ref-type="table-fn" rid="table-fn5-0194599812447048">b</xref></sup></td>
<td/>
<td/>
<td/>
<td/>
<td>.172</td>
</tr>
<tr>
<td> Yes</td>
<td>22</td>
<td>73.3</td>
<td>8</td>
<td>26.7</td>
<td/>
</tr>
<tr>
<td> No</td>
<td>81</td>
<td>84.4</td>
<td>15</td>
<td>15.6</td>
<td/>
</tr>
<tr>
<td>Locoregional recurrences</td>
<td/>
<td/>
<td/>
<td/>
<td>&lt;.001</td>
</tr>
<tr>
<td> Yes</td>
<td>62</td>
<td>79.5</td>
<td>16</td>
<td>20.5</td>
<td/>
</tr>
<tr>
<td> No</td>
<td>306</td>
<td>93.9</td>
<td>20</td>
<td>6.1</td>
<td/>
</tr>
<tr>
<td>Initial treatments</td>
<td/>
<td/>
<td/>
<td/>
<td>.855</td>
</tr>
<tr>
<td> Surgery</td>
<td>281</td>
<td>91.2</td>
<td>27</td>
<td>8.8</td>
<td/>
</tr>
<tr>
<td> Nonsurgical<sup><xref ref-type="table-fn" rid="table-fn6-0194599812447048">c</xref></sup></td>
<td>87</td>
<td>90.6</td>
<td>9</td>
<td>9.4</td>
<td/>
</tr>
<tr>
<td>Chemotherapy</td>
<td/>
<td/>
<td/>
<td/>
<td>.102</td>
</tr>
<tr>
<td> Yes</td>
<td>46</td>
<td>85.2</td>
<td>8</td>
<td>14.8</td>
<td/>
</tr>
<tr>
<td> No</td>
<td>322</td>
<td>92.0</td>
<td>28</td>
<td>8.0</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0194599812447048">
<p>Abbreviations: DM, distant metastasis; LVI, lymphovascular invasion; PNI, perineural invasion.</p>
</fn>
<fn id="table-fn4-0194599812447048">
<label>a</label>
<p>By Fisher exact test or the χ<sup>2</sup> test.</p>
</fn>
<fn id="table-fn5-0194599812447048">
<label>b</label>
<p>Not known in other patients.</p>
</fn>
<fn id="table-fn6-0194599812447048">
<label>c</label>
<p>Including radiotherapy (n = 42), neoadjuvant chemotherapy (n = 28), and concurrent chemoradiotherapy (n = 26).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0194599812447048" position="float">
<label>Table 4.</label>
<caption><p>Multivariate Analyses of Clinicopathologic Factors Predictive of Distant Metastases</p></caption>
<graphic alternate-form-of="table4-0194599812447048" xlink:href="10.1177_0194599812447048-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="center">OR</th>
<th align="center">95% CI</th>
<th align="center"><italic>P</italic><sup><xref ref-type="table-fn" rid="table-fn8-0194599812447048">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>T classification (T1-2 vs T3-4)</td>
<td>2.643</td>
<td>1.080-6.469</td>
<td>.033</td>
</tr>
<tr>
<td>N classification (N0 vs N+)</td>
<td>6.696</td>
<td>2.416-18.557</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>LVI of primary tumors</td>
<td>1.285</td>
<td>0.466-3.540</td>
<td>.628</td>
</tr>
<tr>
<td>PNI of primary tumors</td>
<td>1.355</td>
<td>0.408-4.504</td>
<td>.620</td>
</tr>
<tr>
<td>Locoregional recurrences</td>
<td>4.299</td>
<td>1.662-11.117</td>
<td>.003</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0194599812447048">
<p>Abbreviations: CI, confidence interval; LVI, lymphovascular invasion; OR, odds ratio; PNI, perineural invasion.</p>
</fn>
<fn id="table-fn8-0194599812447048">
<label>a</label>
<p>Binary logistic regression model.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0194599812447048">
<title>Survival of Patients with DM</title>
<p>The median survival period of the 36 patients with DM was 9 months (range, 1-31 months). All 36 patients died of HNSCC-related causes; none died of other causes. Only 3 patients survived for up to 2 years after the diagnosis of DM. The overall 1- and 2-year survival rates of these 36 patients were 40.6% and 13.5%, respectively (<xref ref-type="fig" rid="fig1-0194599812447048"><bold>Figure 1</bold></xref>). When factors predictive of 2-year survival were analyzed, we found that DM to &gt;1 organ was a significant negative predictor of patient survival (<italic>P</italic> &lt; .001; <xref ref-type="table" rid="table5-0194599812447048"><bold>Table 5</bold></xref>; <xref ref-type="fig" rid="fig2-0194599812447048"><bold>Figure 2</bold></xref>). Palliative treatments did not enhance the survival of patients with DM (<italic>P</italic> &gt; .5).</p>
<fig id="fig1-0194599812447048" position="float">
<label>Figure 1.</label>
<caption><p>Kaplan-Meier curve showing the overall survival of 36 patients with distant metastases.</p></caption>
<graphic xlink:href="10.1177_0194599812447048-fig1.tif"/>
</fig>
<fig id="fig2-0194599812447048" position="float">
<label>Figure 2.</label>
<caption><p>Overall survival rates of patients with distant metastases to single and multiple organs.</p></caption>
<graphic xlink:href="10.1177_0194599812447048-fig2.tif"/>
</fig>
<table-wrap id="table5-0194599812447048" position="float">
<label>Table 5.</label>
<caption><p>Cumulative 2-Year Overall Survival Rate according to Clinical Parameters in 36 Patients with Distant Metastases</p></caption>
<graphic alternate-form-of="table5-0194599812447048" xlink:href="10.1177_0194599812447048-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="center">No. of Patients</th>
<th align="center">% 2-Year OSR<sup><xref ref-type="table-fn" rid="table-fn10-0194599812447048">a</xref></sup></th>
<th align="center"><italic>P</italic><sup><xref ref-type="table-fn" rid="table-fn11-0194599812447048">b</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>T classification</td>
<td/>
<td/>
<td>.781</td>
</tr>
<tr>
<td> T1-2</td>
<td>19</td>
<td>15.9</td>
<td/>
</tr>
<tr>
<td> T3-4</td>
<td>17</td>
<td>16.5</td>
<td/>
</tr>
<tr>
<td>N classification</td>
<td/>
<td/>
<td>.294</td>
</tr>
<tr>
<td> N0</td>
<td>6</td>
<td>44.4</td>
<td/>
</tr>
<tr>
<td> N+</td>
<td>30</td>
<td>9.1</td>
<td/>
</tr>
<tr>
<td>Primary tumor site</td>
<td/>
<td/>
<td>.548</td>
</tr>
<tr>
<td> Oral cavity/oropharynx</td>
<td>18</td>
<td>32.0</td>
<td/>
</tr>
<tr>
<td> Larynx</td>
<td>13</td>
<td>15.7</td>
<td/>
</tr>
<tr>
<td> Hypopharynx</td>
<td>5</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>DM to multiple organs</td>
<td/>
<td/>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn13-0194599812447048">d</xref></sup></td>
</tr>
<tr>
<td> No</td>
<td>24</td>
<td>25.7</td>
<td/>
</tr>
<tr>
<td> Yes</td>
<td>12</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>Diagnosis of DM</td>
<td/>
<td/>
<td>.462</td>
</tr>
<tr>
<td> At initial staging</td>
<td>5</td>
<td>66.7</td>
<td/>
</tr>
<tr>
<td> Follow-up</td>
<td>31</td>
<td>13.5</td>
<td/>
</tr>
<tr>
<td>Palliative treatments<sup><xref ref-type="table-fn" rid="table-fn12-0194599812447048">c</xref></sup></td>
<td/>
<td/>
<td>.107</td>
</tr>
<tr>
<td> No</td>
<td>13</td>
<td>10.9</td>
<td/>
</tr>
<tr>
<td> Yes</td>
<td>23</td>
<td>22.0</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0194599812447048">
<p>Abbreviations: DM, distant metastasis; OSR, overall survival rate.</p>
</fn>
<fn id="table-fn10-0194599812447048">
<label>a</label>
<p>Patients surviving 2 years after DM detection.</p>
</fn>
<fn id="table-fn11-0194599812447048">
<label>b</label>
<p>Log-rank test.</p>
</fn>
<fn id="table-fn12-0194599812447048">
<label>c</label>
<p>Including chemotherapy, radiotherapy, and metastasectomy.</p>
</fn>
<fn id="table-fn13-0194599812447048">
<label>d</label>
<p>Cox-proportional hazards model (<italic>P =</italic> .003, hazard ratio = 4.965, 95% confidence interval = 1.745-14.125).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section12-0194599812447048" sec-type="discussion">
<title>Discussion</title>
<p>The incidence of DM is lower in patients with HNSCC than in patients with tumors at other sites.<sup><xref ref-type="bibr" rid="bibr1-0194599812447048">1</xref></sup> Despite this low incidence, however, DMs have an adverse effect on survival and can change treatment plans. An earlier study of 391 patients with HNSCC found that 44 (11.3%) developed DM, with overall survival rates at 1, 3, and 5 years of 56.8%, 9.1%, and 6.8%, respectively.<sup><xref ref-type="bibr" rid="bibr7-0194599812447048">7</xref></sup> Similarly, we found that the overall survival rate at 2 years was only 13.5%, suggesting the need for early identification of patients with HNSCC who are at high risk of developing DM, so that they can be administered more intensive, multimodal treatments including chemotherapy.</p>
<p>We found that the overall incidence of DM in HNSCC patients was 8.9%, similar to previous reports.<sup><xref ref-type="bibr" rid="bibr4-0194599812447048">4</xref><xref ref-type="bibr" rid="bibr5-0194599812447048"/><xref ref-type="bibr" rid="bibr6-0194599812447048"/>-<xref ref-type="bibr" rid="bibr7-0194599812447048">7</xref></sup> Several studies have reported that primary tumors in the hypopharynx, initially advanced T and N stages, histologic grade, and nodal involvement were risk factors associated with the development of DM.<sup><xref ref-type="bibr" rid="bibr3-0194599812447048">3</xref>,<xref ref-type="bibr" rid="bibr6-0194599812447048">6</xref><xref ref-type="bibr" rid="bibr7-0194599812447048"/><xref ref-type="bibr" rid="bibr8-0194599812447048"/><xref ref-type="bibr" rid="bibr9-0194599812447048"/><xref ref-type="bibr" rid="bibr10-0194599812447048"/>-<xref ref-type="bibr" rid="bibr11-0194599812447048">11</xref></sup> We found, however, that advanced T stage, cervical node involvement, and presence of locoregional recurrences were the only independent variables predictive of DM. Although patients with multiple metastatic lymph nodes or multilevel nodal involvement have been reported to be at the highest risk for DM development,<sup><xref ref-type="bibr" rid="bibr5-0194599812447048">5</xref>,<xref ref-type="bibr" rid="bibr6-0194599812447048">6</xref></sup> we found that the numbers and extracapsular extension of involved lymph nodes and multiple involved levels of lymph nodes were not significant factors for the development of DM. In contrast, previous reports<sup><xref ref-type="bibr" rid="bibr12-0194599812447048">12</xref>,<xref ref-type="bibr" rid="bibr13-0194599812447048">13</xref></sup> found that nodal extracapsular spread was the most significant risk factor for DM development in patients with malignancies arising in the oral tongue and larynx.</p>
<p>When we analyzed the predictors of 2-year overall survival of patients with DM, we found no association with primary tumor site, T and N classifications, and palliative treatments for DM. Studies evaluating the impact of palliative care on the quality of life (QOL) and survival of patients with advance-staged cancers found that although palliative care improved patient QOL, it did not affect survival outcomes,<sup><xref ref-type="bibr" rid="bibr14-0194599812447048">14</xref>,<xref ref-type="bibr" rid="bibr15-0194599812447048">15</xref></sup> with another study finding that palliative treatment improved end-of-life experience.<sup><xref ref-type="bibr" rid="bibr16-0194599812447048">16</xref></sup> Although we and others<sup><xref ref-type="bibr" rid="bibr14-0194599812447048">14</xref><xref ref-type="bibr" rid="bibr15-0194599812447048"/>-<xref ref-type="bibr" rid="bibr16-0194599812447048">16</xref></sup> have failed to show that palliative treatments have survival benefits, these treatments may enhance QOL in selected patients who are well-nourished and with good performance status and low tumor burden. This should be further investigated in prospective studies of the relationship between palliative interventions and QOL outcomes in patients with DM of HNSCC.</p>
<p>In agreement with previous findings, we found that the lung was the most common site of DM.<sup><xref ref-type="bibr" rid="bibr3-0194599812447048">3</xref>,<xref ref-type="bibr" rid="bibr4-0194599812447048">4</xref></sup> Pulmonary metastasectomy was shown to increase median survival time to 26 months and the overall 5-year survival rate to 26.5%.<sup><xref ref-type="bibr" rid="bibr17-0194599812447048">17</xref></sup> We found that metastases to multiple organs negatively affected the 2-year overall survival of patients with DM. Palliative chemotherapy and supportive care may be beneficial, however, in patients with low probability for long-term survival. Communicating with these patients about their prognosis and preparation for death was found to be very important.<sup><xref ref-type="bibr" rid="bibr18-0194599812447048">18</xref>,<xref ref-type="bibr" rid="bibr19-0194599812447048">19</xref></sup></p>
</sec>
<sec id="section13-0194599812447048" sec-type="conclusions">
<title>Conclusion</title>
<p>In conclusion, we have identified a subset of patients with HNSCC who are at high risk of developing DM. Patients with advanced T stage, involvement of cervical nodes, and presence of locoregional recurrences may require more surveillance and comprehensive follow-up for the development of DM. Patients with DM to a single organ may survive longer than those with DMs to multiple organs. Our results may help identify and properly manage patients at high risk for DM.</p>
</sec>
<sec id="section14-0194599812447048">
<title>Author Contributions</title>
<p><bold>Dong Hwan Lee</bold>, data acquisition, interpretation of data, manuscript preparation; <bold>Min Joo Kim</bold>, data acquisition; <bold>Jong-Lyel Roh</bold>, hypothesis, design of study, manuscript preparation; <bold>Sung-Bae Kim</bold>, data acquisition, interpretation of data; <bold>Seung-Ho Choi</bold>, data acquisition, manuscript preparation; <bold>Soon Yuhl Nam</bold>, data acquisition, manuscript preparation; <bold>Sang Yoon Kim</bold>, data acquisition, manuscript preparation.</p>
</sec>
<sec id="section15-0194599812447048">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> None.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>No sponsorships or competing interests have been disclosed for this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599812447048">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jemal</surname><given-names>A</given-names></name>
<name><surname>Bray</surname><given-names>F</given-names></name>
<name><surname>Center</surname><given-names>MM</given-names></name>
<name><surname>Ferlay</surname><given-names>J</given-names></name>
<name><surname>Ward</surname><given-names>E</given-names></name>
<name><surname>Forman</surname><given-names>D</given-names></name>
</person-group>. <article-title>Global cancer statistics</article-title>. <source>CA Cancer J Clin</source>. <year>2011</year>;<volume>61</volume>:<fpage>69</fpage>-<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr2-0194599812447048">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Boyle</surname><given-names>P</given-names></name>
<name><surname>Levin</surname><given-names>B</given-names></name>
</person-group>. <source>World Cancer Report 2008</source>. <publisher-loc>The International Agency for Research on Cancer. Geneva, Switzerland</publisher-loc>: <publisher-name>WHO Press</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr3-0194599812447048">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferlito</surname><given-names>A</given-names></name>
<name><surname>Shaha</surname><given-names>AR</given-names></name>
<name><surname>Silver</surname><given-names>CE</given-names></name>
<name><surname>Rinaldo</surname><given-names>A</given-names></name>
<name><surname>Mondin</surname><given-names>V</given-names></name>
</person-group>. <article-title>Incidence and sites of distant metastases from head and neck cancer</article-title>. <source>ORL J Otorhinolaryngol Relat Spec</source>. <year>2001</year>;<volume>63</volume>:<fpage>202</fpage>-<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr4-0194599812447048">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuperman</surname><given-names>DI</given-names></name>
<name><surname>Auethavekiat</surname><given-names>V</given-names></name>
<name><surname>Adkins</surname><given-names>DR</given-names></name>
<etal/>
</person-group>. <article-title>Squamous cell cancer of the head and neck with distant metastasis at presentation</article-title>. <source>Head Neck</source>. <year>2011</year>;<volume>33</volume>:<fpage>714</fpage>-<lpage>718</lpage>.</citation>
</ref>
<ref id="bibr5-0194599812447048">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Studer</surname><given-names>G</given-names></name>
<name><surname>Seifert</surname><given-names>B</given-names></name>
<name><surname>Glanzmann</surname><given-names>C</given-names></name>
</person-group>. <article-title>Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pre-treatment staging?</article-title> <source>Strahlenther Onkol</source>. <year>2008</year>;<volume>184</volume>:<fpage>580</fpage>-<lpage>585</lpage>.</citation>
</ref>
<ref id="bibr6-0194599812447048">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garavello</surname><given-names>W</given-names></name>
<name><surname>Ciardo</surname><given-names>A</given-names></name>
<name><surname>Spreafico</surname><given-names>R</given-names></name>
<name><surname>Gaini</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Risk factors for distant metastases in head and neck squamous cell carcinoma</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>2006</year>;<volume>132</volume>:<fpage>762</fpage>-<lpage>766</lpage>.</citation>
</ref>
<ref id="bibr7-0194599812447048">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Di</surname><given-names>B</given-names></name>
<name><surname>Shang</surname><given-names>Y</given-names></name>
<name><surname>Zhou</surname><given-names>Y</given-names></name>
<name><surname>Cheng</surname><given-names>J</given-names></name>
<name><surname>He</surname><given-names>Z</given-names></name>
</person-group>. <article-title>Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas</article-title>. <source>Eur J Surg Oncol</source>. <year>2009</year>;<volume>35</volume>:<fpage>1348</fpage>-<lpage>1353</lpage>.</citation>
</ref>
<ref id="bibr8-0194599812447048">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doweck</surname><given-names>I</given-names></name>
<name><surname>Robbins</surname><given-names>KT</given-names></name>
<name><surname>Vieira</surname><given-names>F</given-names></name>
</person-group>. <article-title>Analysis of risk factors predictive of distant failure after targeted chemoradiation for advanced head and neck cancer</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>2001</year>;<volume>127</volume>:<fpage>1315</fpage>-<lpage>1318</lpage>.</citation>
</ref>
<ref id="bibr9-0194599812447048">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>León</surname><given-names>X</given-names></name>
<name><surname>Quer</surname><given-names>M</given-names></name>
<name><surname>Orús</surname><given-names>C</given-names></name>
<name><surname>del Prado Venegas</surname><given-names>M</given-names></name>
<name><surname>López</surname><given-names>M</given-names></name>
</person-group>. <article-title>Distant metastases in head and neck cancer patients who achieved loco-regional control</article-title>. <source>Head Neck</source>. <year>2000</year>;<volume>22</volume>:<fpage>680</fpage>-<lpage>686</lpage>.</citation>
</ref>
<ref id="bibr10-0194599812447048">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ljumanovic</surname><given-names>R</given-names></name>
<name><surname>Langendijk</surname><given-names>JA</given-names></name>
<name><surname>Hoekstra</surname><given-names>OS</given-names></name>
<name><surname>Leemans</surname><given-names>CR</given-names></name>
<name><surname>Castelijns</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Distant metastases in head and neck carcinoma: identification of prognostic groups with MR imaging</article-title>. <source>Eur J Radiol</source>. <year>2006</year>;<volume>60</volume>:<fpage>58</fpage>-<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr11-0194599812447048">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alvi</surname><given-names>A</given-names></name>
<name><surname>Johnson</surname><given-names>JT</given-names></name>
</person-group>. <article-title>Development of distant metastasis after treatment of advanced-stage head and neck cancer</article-title>. <source>Head Neck</source>. <year>1997</year>;<volume>19</volume>:<fpage>500</fpage>-<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr12-0194599812447048">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Myers</surname><given-names>JN</given-names></name>
<name><surname>Greenberg</surname><given-names>JS</given-names></name>
<name><surname>Mo</surname><given-names>V</given-names></name>
<name><surname>Roberts</surname><given-names>D</given-names></name>
</person-group>. <article-title>Extracapsular spread: a significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue</article-title>. <source>Cancer</source>. <year>2001</year>;<volume>92</volume>:<fpage>3030</fpage>-<lpage>3036</lpage>.</citation>
</ref>
<ref id="bibr13-0194599812447048">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oosterkamp</surname><given-names>S</given-names></name>
<name><surname>de Jong</surname><given-names>JM</given-names></name>
<name><surname>Van den Ende</surname><given-names>PL</given-names></name>
<name><surname>Manni</surname><given-names>JJ</given-names></name>
<name><surname>Dehing-Oberije</surname><given-names>C</given-names></name>
<name><surname>Kremer</surname><given-names>B</given-names></name>
</person-group>. <article-title>Predictive value of lymph node metastases and extracapsular extension for the risk of distant metastases in laryngeal carcinoma</article-title>. <source>Laryngoscope</source>. <year>2006</year>;<volume>116</volume>:<fpage>2067</fpage>-<lpage>2070</lpage>.</citation>
</ref>
<ref id="bibr14-0194599812447048">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yun</surname><given-names>YH</given-names></name>
<name><surname>Lee</surname><given-names>MK</given-names></name>
<name><surname>Kim</surname><given-names>SY</given-names></name>
<etal/>
</person-group>. <article-title>Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>:<fpage>2474</fpage>-<lpage>2480</lpage>.</citation>
</ref>
<ref id="bibr15-0194599812447048">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakitas</surname><given-names>M</given-names></name>
<name><surname>Lyons</surname><given-names>KD</given-names></name>
<name><surname>Hegel</surname><given-names>MT</given-names></name>
<etal/>
</person-group>. <article-title>Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>:<fpage>741</fpage>-<lpage>749</lpage>.</citation>
</ref>
<ref id="bibr16-0194599812447048">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shuman</surname><given-names>AG</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Taylor</surname><given-names>JM</given-names></name>
<name><surname>Prince</surname><given-names>ME</given-names></name>
</person-group>. <article-title>End-of-life care among head and neck cancer patients</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2011</year>;<volume>144</volume>:<fpage>733</fpage>-<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr17-0194599812447048">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shiono</surname><given-names>S</given-names></name>
<name><surname>Kawamura</surname><given-names>M</given-names></name>
<name><surname>Sato</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas</article-title>. <source>Ann Thorac Surg</source>. <year>2009</year>;<volume>88</volume>:<fpage>856</fpage>-<lpage>860</lpage>.</citation>
</ref>
<ref id="bibr18-0194599812447048">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sciubba</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>End of life considerations in the head and neck cancer patient</article-title>. <source>Oral Oncol</source>. <year>2009</year>;<volume>45</volume>:<fpage>431</fpage>-<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr19-0194599812447048">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Genden</surname><given-names>EM</given-names></name>
<name><surname>Ferlito</surname><given-names>A</given-names></name>
<name><surname>Bradley</surname><given-names>PJ</given-names></name>
<name><surname>Rinaldo</surname><given-names>A</given-names></name>
<name><surname>Scully</surname><given-names>C</given-names></name>
</person-group>. <article-title>Neck disease and distant metastases</article-title>. <source>Oral Oncol</source>. <year>2003</year>;<volume>39</volume>:<fpage>207</fpage>-<lpage>212</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>